Clinical Trial Update: HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

The Phase 2 HiPED trial evaluating high-dose ranibizumab (Lucentis) for persistent pigment epithelial detachments in age-related macular degeneration has been t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Anne Fung MD | Conditions: Wet Macular Degeneration, Macular Degeneration | Phase 2 | Status: TERMINATED